Are Options Traders Bullish on ARDM?
Let daily Option Order Flow show you where stock investors are Bullish and Bearish!!! Receive a FREE daily email of the Market Chameleon Order Flow Sentiment Newsletter.
Market Chameleon

About ARDM

Aradigmis an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases.Aradigmis currently in Phase 3 development of Pulmaquin (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigm's inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax. In addition,Aradigmhas a pipeline composed of programs to prevent diseases in tobacco smokers through smoking cessation and a diagnostic program to detect aspirations of gastrointestinal fluid into the respiratory tract.
Primary Exchange: NASDAQ
SIC Electromedical & Electrotherapeutic Apparatus
NAICS Electromedical and Electrotherapeutic Apparatus Manufacturing

ARDM is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 15.6 B 1.55972E+10 3,389 3389 0.0% 0 2 K 2108

Wait, Before You Leave...